No Data
No Data
Pacific Biosciences of California (PACB) Advances While Market Declines: Some Information for Investors
Barclays Maintains Pacific Biosciences of California(PACB.US) With Hold Rating, Maintains Target Price $2
Barclays analyst Luke Sergott maintains $Pacific Biosciences of California(PACB.US)$ with a hold rating, and maintains the target price at $2.According to TipRanks data, the analyst has a success rate
PacBio, Form Bio Team Up to Launch Initiatives to Unify AAV Gene Therapy Industry
PacBio (PACB) and Form Bio, a provider of life sciences technology, said Thursday they are launching initiatives to advance and unify the adeno-associated viral, or AAV, gene therapy industry. Financi
Cathie Wood's Top and Bottom Performing ARKK Holdings of H1
Pacific Biosciences of California, Inc (PACB): A Good Buy According to Analysts?
Form Bio and PacBio Announce Collaboration to Launch New Resources Set to Transform AAV Design and Analysis Best Practices
Companies Form Expert Working Group to Introduce Essential Tools for AAV Development and Research ProfessionalsSAN FRANCISCO / ACCESSWIRE / June 27, 2024 / Form Bio, the provider of advanced computati
No Data